An independent medical advisory board is reviewing a newly developed oral agent for the prevention of major adverse cardiovascular events (MACE) in patients with familial hypercholesterolemia. They are analyzing -year outcome data from a randomized, placebo-controlled trial to evaluate the drug's net clinical benefit.
The trial provides the following cumulative incidence data over the -year study period:
- Baseline risk (placebo group) of MACE:
- Relative risk (RR) of MACE with the new agent:
- Baseline risk (placebo group) of drug-induced hepatotoxicity:
- Relative risk (RR) of drug-induced hepatotoxicity with the new agent:
Based on these findings, what is the absolute difference between the Number Needed to Harm (NNH) for hepatotoxicity and the Number Needed to Treat (NNT) to prevent one MACE over the -year period?
(Enter the exact whole number.)
Cevap: 40